Results 111 to 120 of about 12,455 (266)
Immunological Reviews, Volume 328, Issue 1, Page 221-242, November 2024.Summary Advances in antibody technologies have resulted in the development of potent antibody‐based therapeutics with proven clinical efficacy against infectious diseases. Several monoclonal antibodies (mAbs), mainly against viruses such as SARS‐CoV‐2, HIV‐1, Ebola virus, influenza virus, and hepatitis B virus, are currently undergoing clinical testing
Julia E. Edgar, Stylianos Bournazos
wiley +1 more source
Characterization of Sudan Ebolavirus infection in ferrets
Oncotarget, 2017 Sudan virus (SUDV) outbreaks in Africa are highly lethal; however, the development and testing of novel antivirals and vaccines for this virus has been limited by a lack of suitable animal models. Non-human primates (NHP) remain the gold standard for modeling filovirus disease, but they are not conducive to screening large numbers of experimental ...
Andrea Kroeker +11 more
openaire +3 more sources
The face of Ebola: changing frequency of haemorrhage in the West African compared with Eastern-Central African outbreaks [PDF]
, 2015 BACKGROUND: The West-African (WA) Zaire Ebolavirus disease (EVD) outbreak was characterized by an exceptionally high number of cases and deaths as compared with the Eastern-Central African (ECA) outbreaks.
Crispian Scully +4 more
core +4 more sources
bioRxiv, 2022 Understanding the human antibody response to emerging viral pathogens is key to epidemic preparedness. As the size of the B cell response to a pathogenic virus protective antigen is undefined, we performed deep paired heavy and light chain sequencing in ...
E. Chen +21 more
semanticscholar +1 more source
Ebolavirus and Haemorrhagic Syndrome.
Sultan Qaboos University medical journal, 2015 The Ebola virus is a highly virulent, single-stranded ribonucleic acid virus which affects both humans and apes and has fast become one of the world's most feared pathogens. The virus induces acute fever and death, with haemorrhagic syndrome occurring in up to 90% of patients.
Gerald A. Matua +2 more
openaire +3 more sources
Suspected Ebolavirus Reservoir Species in Anthropogenic Landscapes
The Bulletin of the Ecological Society of America, Volume 106, Issue 2, April 2025.
Matthew LeBreton, Robert L. Cohen
wiley +1 more source
Vaccine process technology—A decade of progress
Biotechnology and Bioengineering, Volume 121, Issue 9, Page 2604-2635, September 2024.Abstract In the past decade, new approaches to the discovery and development of vaccines have transformed the field. Advances during the COVID‐19 pandemic allowed the production of billions of vaccine doses per year using novel platforms such as messenger RNA and viral vectors.
Barry Buckland +8 more
wiley +1 more source
Replication-Deficient Ebolavirus as a Vaccine Candidate [PDF]
Journal of Virology, 2009 ABSTRACT Ebolavirus causes severe hemorrhagic fever, with case fatality rates as high as 90%. Currently, no licensed vaccine is available against Ebolavirus. We previously generated a replication-deficient, biologically contained Ebolavirus, EbolaΔVP30, which lacks the essential VP30 gene, grows only in cells stably expressing ...
Shinji Watanabe +11 more
openaire +3 more sources
Survey of clinical features, pathogenesis and therapeutic options for Ebola haemorrhagic fever [PDF]
, 2015 The genus Ebola virus first was recognized in 1976, when two outbreaks occurred in Zaire and Sudan. Ebola virus disease (EVD) is a highly contagious disease that can affect both human and nonhuman primates: Zaire ebolavirus (ZEBOV), Sudan ...
Azad, Mehdi +3 more
core +2 more sources
Endoplasmic reticulum stress in diseases
MedComm, Volume 5, Issue 9, September 2024.The endoplasmic reticulum (ER) serves as a vital organelle in eukaryotic cells, performing essential roles such as protein folding, modification, and trafficking, lipid biosynthesis, and calcium regulation. Various conditions may disrupt ER function, potentially leading to the accumulation of unfolded and misfolded proteins, and triggering ER stress ...
Yingying Liu +5 more
wiley +1 more source